Investigation of the Enhancement of the Response to Hepatitis B Vaccine by Lenalidomide (RevlimidTM, CC-5013) in Plasma Cell Dyscrasias

Trial Profile

Investigation of the Enhancement of the Response to Hepatitis B Vaccine by Lenalidomide (RevlimidTM, CC-5013) in Plasma Cell Dyscrasias

Completed
Phase of Trial: Phase II

Latest Information Update: 27 May 2016

At a glance

  • Drugs Lenalidomide (Primary) ; Hepatitis B vaccine
  • Indications Hepatitis B
  • Focus Pharmacodynamics
  • Sponsors Boston VA Research Institute
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 10 Apr 2016 Status changed from active, no longer recruiting to completed.
    • 24 Feb 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top